Swiss firm Cimex AG's clopidogrel, a generic form of Sanofi-Aventis' Plavix, has been approved in its home market. The French drug major, which originated the blockbuster blood clotting drug, has already filed legal action against Cimex and noted that the rival product contains a different salt of the active ingredient used in Plavix. Two marketing partners are expected to launch the agent in Germany. According to Cimex, applications for additional European countries are in preparation.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze